subscribeSubscribe
price-trendAsk Us
Health Canada Issues Recall of IDHIFA (enasidenib mesylate)

Health Canada Issues Recall of IDHIFA (enasidenib mesylate)
HEALTH CANADA
08 Jun 2023
Share Share
Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial

Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial
BUSINESSWIRE
25 Aug 2020
Share Share
Bristol Myers Squibb`s targeted AML drug Idhifa fails to extend patients` lives

Bristol Myers Squibb`s targeted AML drug Idhifa fails to extend patients` lives
Angus Liu FIERCEPHARMA
25 Aug 2020
Share Share
Agios, seeking a new strategy, touts positive data and marketing deal

Agios, seeking a new strategy, touts positive data and marketing deal
Jacob Bell BIOPHARMADIVE
13 Jun 2020
Share Share
Medicare Part D no match for runaway specialty drug costs: study

Medicare Part D no match for runaway specialty drug costs: study
Mark Miller REUTERS
07 Feb 2019
Share Share
Agios wins FDA nod for targeted AML drug Tibsovo

Agios wins FDA nod for targeted AML drug Tibsovo
E. Sagonowsky FIERCE PHARMA
23 Jul 2018
Share Share
Agios scores its second new drug approval, ivosidenib heads to the AML market

Agios scores its second new drug approval, ivosidenib heads to the AML market
John Carroll ENDPTS
21 Jul 2018
Share Share
After some stinging setbacks question high failure ratE Celgene’s drug pipeline

After some stinging setbacks question high failure ratE Celgene’s drug pipeline
John Carroll ENDPTS
26 May 2018
Share Share